Nondiabetic Kidney Disease

[1]  G. Navis,et al.  Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism , 2009, Nature Reviews Nephrology.

[2]  G. Remuzzi,et al.  Proteinuria: Is the ONTARGET renal substudy actually off target? , 2009, Nature Reviews Nephrology.

[3]  G. Remuzzi,et al.  Proteinuria: Increased angiotensin-receptor blocking is not the first option , 2009, Nature Reviews Nephrology.

[4]  G. Remuzzi,et al.  Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. , 2009, The American journal of pathology.

[5]  N. Perico,et al.  Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection , 2008, Nature Reviews Drug Discovery.

[6]  L. Fried.  Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. , 2008, Kidney international.

[7]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[8]  N. Perico,et al.  The aggravating mechanisms of aldosterone on kidney fibrosis. , 2008, Journal of the American Society of Nephrology : JASN.

[9]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[10]  J. Ingelfinger.  Aliskiren and dual therapy in type 2 diabetes mellitus. , 2008, The New England journal of medicine.

[11]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  R. Kunz,et al.  The COOPERATE trial: a letter of concern , 2008, The Lancet.

[13]  S. Mizuno,et al.  HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. , 2008, Frontiers in bioscience : a journal and virtual library.

[14]  B. Pussell,et al.  Adult nephrotic syndrome: Non‐specific strategies for treatment (Review Article) , 2008, Nephrology.

[15]  G. Remuzzi,et al.  Intensified inhibition of renin-angiotensin system: A way to improve renal protection? , 2007, Current hypertension reports.

[16]  Ping-yan Chen,et al.  Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  G. Remuzzi,et al.  How does proteinuria cause progressive renal damage? , 2006, Journal of the American Society of Nephrology : JASN.

[18]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[19]  G. Remuzzi,et al.  ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.

[20]  G. Remuzzi,et al.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. , 2006, The Journal of clinical investigation.

[21]  D. Batlle,et al.  Antiproteinuric effect of oral paricalcitol in chronic kidney disease. , 2005, Kidney international.

[22]  G. Striker,et al.  Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. , 2005, The American journal of pathology.

[23]  F. Cheema,et al.  The renal papilla is a niche for adult kidney stem cells. , 2004, The Journal of clinical investigation.

[24]  N. Perico,et al.  Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[25]  Y. Nojima,et al.  Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. , 2003, Journal of the American Society of Nephrology : JASN.

[26]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[27]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[28]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[29]  G. Remuzzi,et al.  Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.

[30]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[31]  G. Remuzzi,et al.  Transforming Growth Factor- (cid:1) 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins A Central Pathway in Progressive Glomerulosclerosis , 2022 .

[32]  B. Brenner,et al.  Combination ACEI and ARB therapy: additional benefit in renoprotection? , 2002, Current opinion in nephrology and hypertension.

[33]  E. Ritz,et al.  Smoking and the kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[34]  G. Remuzzi,et al.  Effect of combining ACE inhibitor and statin in severe experimental nephropathy. , 2002, Kidney international.

[35]  M. Bartal.  Health effects of tobacco use and exposure. , 2001, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[36]  M. Okabe,et al.  Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. , 2001, Journal of the American Society of Nephrology : JASN.

[37]  G. Remuzzi,et al.  ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.

[38]  R. Poulsom,et al.  Bone marrow contributes to renal parenchymal turnover and regeneration , 2001, The Journal of pathology.

[39]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[40]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[41]  V. D’Agati,et al.  Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. , 2000, Kidney international.

[42]  K. Matsumoto,et al.  Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. , 1999, Hypertension.

[43]  M. Seiki,et al.  Regulation of matrix metalloproteinase‐2 (MMP‐2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP‐2 expression and activation accompanying up‐regulation of membrane type‐1 MMP , 1999, International journal of cancer.

[44]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[45]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[46]  H. Wedel,et al.  Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  G. Navis,et al.  ACE-inhibitors: panacea for progressive renal disease? , 1997, The Lancet.

[48]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[49]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[50]  B. Kasiske,et al.  Renal injury of diet-induced hypercholesterolemia in rats. , 1990, Kidney international.

[51]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.

[52]  C. Mogensen.  Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. , 1976, Scandinavian journal of clinical and laboratory investigation.

[53]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[54]  G. Remuzzi,et al.  Halting the progression of renal disease: where we stand? , 2002, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[55]  W. Keane,et al.  Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. , 1996, Mineral and electrolyte metabolism.